Kiora Pharmaceuticals Files 8-K

Ticker: KPHMW · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1372514

Kiora Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyKiora Pharmaceuticals Inc (KPHMW)
Form Type8-K
Filed DateJun 4, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-action, financial-reporting

Related Tickers: KPRX

TL;DR

Kiora Pharma filed an 8-K on June 4th, watch for shareholder votes & financials.

AI Summary

Kiora Pharmaceuticals, Inc. filed an 8-K on June 4, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The company, formerly known as Eyegate Pharmaceuticals Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates important corporate actions and financial reporting by Kiora Pharmaceuticals, which could impact investors' understanding of the company's status and future direction.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating immediate significant risk.

Key Numbers

  • 001-36672 — Commission File Number (Identifies the company's SEC filing history)

Key Players & Entities

  • Kiora Pharmaceuticals, Inc. (company) — Registrant
  • Eyegate Pharmaceuticals Inc. (company) — Former name
  • June 4, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

What is the primary business of Kiora Pharmaceuticals, Inc.?

Kiora Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.

When was Kiora Pharmaceuticals, Inc. formerly known as?

Kiora Pharmaceuticals, Inc. was formerly known as Eyegate Pharmaceuticals Inc.

What is the company's principal executive office address?

The company's business and mail address is 332 Encinitas Boulevard, Suite 102, Encinitas, CA 92024.

What is the fiscal year end for Kiora Pharmaceuticals, Inc.?

The fiscal year end for Kiora Pharmaceuticals, Inc. is December 31st.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding KIORA PHARMACEUTICALS INC (KPHMW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.